bococizumab
mAbexperimental
Bococizumab is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders." — Wikipedia
Clinical trial activity
23 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
14
Phase 3
10
Phase 4
0
Earliest trial started Nov 1, 2009 (NCT00991159)
Timeline
Indications
Mechanism of action
- Subtilisin/kexin type 9INHIBITOR
PCSK9 inhibitor
PCSK9 causes the degradation of LDLR, then inhibiting PCSK9 would mean prolonging the lifespan of LDLR, which would lead to drastic reductions in plasma LDL-C levels.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBococizumab ↗
- ChEMBLCHEMBL3137349 ↗
Also known as
- bococizumab
- bococizumab
- bococizumab
- bococizumab
- pf-04950615
- pf-04950615
- rn316
- rn316
- rn-316
- rn316 antibody
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02947334 | Phase 3 | Oct 1, 2016 | Pfizer |
| NCT02524106 | Phase 3 | Aug 1, 2016 | Pfizer, University of California, San Francisco |
| NCT02667223 | Phase 1 | Feb 1, 2016 | Halozyme Therapeutics, Pfizer |
| NCT02458287 | Phase 3 | Jun 1, 2015 | Pfizer |
| NCT02458209 | Phase 1 | May 1, 2015 | Pfizer |
| NCT02100514 | Phase 3 | Oct 1, 2014 | Pfizer |
| NCT02135029 | Phase 3 | Jun 1, 2014 | Pfizer |
| NCT02043301 | Phase 1 | Apr 1, 2014 | Pfizer |
| NCT02055976 | Phase 2 | Mar 1, 2014 | Pfizer |
| NCT01975389 | Phase 3 | Oct 29, 2013 | Pfizer |
| NCT01975376 | Phase 3 | Oct 29, 2013 | Pfizer |
| NCT01968980 | Phase 3 | Oct 1, 2013 | Pfizer |
| NCT01968954 | Phase 3 | Oct 1, 2013 | Pfizer |
| NCT01968967 | Phase 3 | Oct 1, 2013 | Pfizer |
| NCT01720537 | Phase 1 | Jul 1, 2012 | Pfizer |
| NCT01592240 | Phase 2 | Jul 1, 2012 | Pfizer |
| NCT01435382 | Phase 1 | Oct 1, 2011 | Pfizer |
| NCT01342211 | Phase 2 | Jul 1, 2011 | Pfizer |
| NCT01350141 | Phase 2 | Jun 1, 2011 | Pfizer |
| NCT01243151 | Phase 1 | Feb 1, 2011 | Pfizer |
Showing 20 of 23 trials
Page 1 / 2
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 23 | 22 | 3 | 2009 |
| Halozyme Therapeutics | For profit | 1 | 0 | 1 | 2016 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2016 |
3 organizations
Page 1 / 1